The interactions of platelets with fibrinogen mediate a variety of responses including adhesion, platelet aggregation and fibrin clot retraction. While it was assumed that interactions of the platelet integrin α IIb β 3 with the AGDV sequence in the γC-domain of fibrinogen and/or RGD sites in the Aα chains are involved in clot retraction and adhesion, recent data demonstrated that fibrinogen lacking these sites still supported clot retraction. These findings suggested that an unknown site in fibrinogen and/or other integrins participate in clot retraction. Here we have identified a sequence within γC that mediates binding of fibrinogen to platelets. Synthetic peptide duplicating the 365-383 sequence in γC, designated P3, efficiently inhibited clot retraction in a dose-dependent manner. Furthermore, P3 supported platelet adhesion and was an effective inhibitor of platelet adhesion to fibrinogen fragments. Analysis of overlapping peptides spanning P3 and mutant recombinant γC-domains demonstrated that the P3 activity is contained primarily within γ370-383. Integrins α IIb β 3 and α 5 β 1 were implicated in recognition of P3, as platelet adhesion to the peptide was blocked by function-blocking mAbs against these receptors. Direct evidence that α IIb β 3 and α 5 β 1 bind P3 was obtained by selective capture of these integrins from platelet lysates using a P3-affinity matrix. Thus, these data suggest that the P3 sequence in the γC-domain of fibrinogen defines a previously unknown recognition specificity of α IIb β 3 and α 5 β 1 and may function as a binding site for these integrins.
INTRODUCTION
The process of thrombus formation upon vascular injury is a complex series of events that involves platelets and plasma proteins, including fibrinogen (Fg) 1 . Adhesive reactions of platelets with Fg are required for platelet aggregation, which triggers subsequent formation of a blood clot composed of insoluble fibrin and captured platelets. The interactions of platelets with fibrin within platelet-rich thrombi result in clot retraction which is visually manifested in a dramatic reduction in fibrin gel volume. The mechanism and physiological significance of platelet-mediated fibrin clot retraction remains poorly understood, but it has been suggested that contraction of fibrin clots may be required for clearance of the thrombus and also may facilitate wound healing.
The primary interactions of platelets with Fg and fibrin are mediated by the plateletspecific receptor α IIb β 3 (glycoprotein IIbIIIa), a member of the integrin family of receptors.
α IIb β 3 is the most abundant integrin on the platelet surface and is expressed at ∼ 80,000 copies per cell (1) . Numerous studies using synthetic peptides and function blocking antibodies have demonstrated that three sites in Fg can potentially interact with α IIb β 3 upon platelet adhesion and aggregation (1) . Because Fg consists of two identical disulfide-bonded subunits, each of 4 parts of the γ-chains of Fg, and which contain AGDV, are the primary sites for interactions with the receptor (3). This conclusion has also been supported by experiments with recombinant Fg in which mutation of AGDV in γC resulted in the loss of platelet aggregation while mutations of both RGD sites in the Aα chain had no effect (4, 5) .
Several previous reports have demonstrated that α IIb β 3 plays an important role in plateletmediated clot retraction. Platelets isolated from patients with Glanzmann's thrombasthenia, a bleeding disorder in which α IIb β 3 is dysfunctional or absent, were defective in clot retraction (6) . Furthermore, monoclonal antibodies directed against α IIb β 3 and Fg recognition peptides, which inhibit Fg binding to platelets and platelet aggregation, blocked clot retraction (7) (8) (9) (10) .
However, in contrast to platelet aggregation, the AGDV sequence in the γC-domain is not absolutely required for clot retraction. Recombinant human Fg which lacks AGDV sequences did not support platelet aggregation but still supported normal clot retraction that was indistinguishable from retraction mediated by normal recombinant or plasma Fg (11) . In addition, mice in which the γ-chain gene was targeted to eliminate the C-terminus of the γ-chain of Fg manifested bleeding associated with impaired platelet aggregation, but clot retraction was normal (12) . These results suggested that the sites in Fg that are required for platelet aggregation differ from the sites that are required for clot retraction. Therefore, it was proposed that RGD sites in the Aα-chains can mediate clot retraction (13) . However, when this hypothesis was tested directly using recombinant Fg in which RGDs were mutated, this mutant Fg exhibited normal clot retraction (13) . It is noteworthy that when two RGD sites and AGDV in the γC-domain were all mutated, only the rate of clot retraction mediated by Fg containing a triple mutation was delayed while the final extent of clot retraction was similar to that produced by wild-type recombinant Fg (13) . Taken together, these findings suggested that clot 5 retraction is a two-step process, such that AGDV sites in the γC-domains are important for initial binding to α IIb β 3 and may be involved in the initial step of clot retraction. The second step, the development of clot tension, does not depend exclusively on either AGDV or RGD sites. Thus, such a model suggests involvement of a novel binding site in Fg that is engaged by α IIb β 3 and/or other integrin(s) in the second step of clot remodeling.
In this study, we have sought to localize the binding site in Fg which participates in platelet-mediated clot retraction. Guided by a lead that mAb 2G5 inhibited clot retraction, we have identified a novel recognition sequence in the γC-domain of Fg, γ370-383, and demonstrated that two platelet integrins, α IIb β 3 and α 5 β 1 , bind this sequence during clot retraction and platelet adhesion. Laboratories) and purified as described previously (14, 15 NGIIWATWKTRWYSMKKTT, a series of overlapping peptides spanning this sequence, and a scrambled γ370-383 peptide (P3′-scr) (Table 1) were synthesized using Fmoc chemistry and purified by HPLC on a preparative C18 Vydac column using a 5-90% linear gradient of acetonitrile in 0.1% trifluoroacetic acid. Authenticity and purity of the peptides were verified by mass spectroscopy. In addition, the Fg peptide γ400-411 (H12) was synthesized. Peptides duplicating γ340-357, γ351-370, and γ383-395 of Fg (designated H19, H20 and P2-C, respectively) and the IIICS-1 peptide of fibronectin were previously described (16, 17 In inhibition experiments, platelets were mixed with different concentrations of peptides or mAbs for 20 min at 22°C before they were added to the wells coated with adhesive substrates. MnCl 2 , containing 0.2% Triton X-100 reduced, pH 7.4), and bound material was eluted with a buffer A containing 2 mg/ml P3. Proteins strongly bound to the affinity matrix were eluted with TBS buffer containing 4 M urea. The samples were subjected to SDS-PAGE on 7.5% gels under non-reducing conditions followed by Western blotting using anti-integrin subunit specific and anti-Fg mAbs. Proteins in the gels were transferred to Immobilon-P membranes (Millipore) and the membranes were incubated with mAbs against α IIb (CD41, 3 µg/ml), β 3 (AP3, 0.5 µg/ml), β 1 (1965, 1 µg/ml), polyclonal anti-α 5 antibody (1928) at 1:5000 dilution and anti-Fg mAb 4-2 (5 µg/ml). Bound antibodies were detected by reaction with a peroxidaseconjugated second antibody (Bio-Rad) followed by addition of SuperSignal Chemiluminescent substrate (Pierce). The integrin subunits were identified on the basis of positive staining and characteristic molecular weight.
Affinity chromatography of platelet lysates -

RESULTS
Inhibition of platelet-mediated fibrin clot retraction by mAb 2G5 -Previous studies have
demonstrated that mAb 2G5 inhibited agonist-induced platelet aggregation (18) . This mAb recognizes the Fg sequence γ365-383 in the γC-domain and, thus, does not appear to compete with AGDV at γ408-411, the binding site for platelet integrin α IIb β 3 (18) . In fact, previous data have indicated that mAb 2G5 had no effect on binding of radiolabeled Fg to stimulated platelets (18) . We have further examined whether mAb 2G5 affects platelet-mediated fibrin clot retraction. The mAb inhibited clot retraction in a dose-dependent manner: 50% inhibition was attained at ∼15 µg/ml mAb, and 50 µg/ml produced complete inhibition. The potency of mAb 2G5 was similar to that of Fab 7E3 which binds platelet integrins α IIb β 3 and α V β 3 and inhibits clot retraction (10, 25, 26) . In addition, the effect of mAb 2G5 was similar to that of mAb 4A5 (IC 50 ~10 µg/ml) directed against the binding site for α IIb β 3 at γ408-411 (21), and which inhibits platelet adhesion (27) and clot retraction (26) . Two other anti-Fg mAbs, 3G11
and 2F10, which have specificity overlapping with that of mAb 2G5 (19) also efficiently blocked clot retraction.
Effect of γ365-383 on clot retraction -Based on the recognition specificity of mAb 2G5, we hypothesized that a peptide duplicating its epitope might block clot retraction.
Accordingly, we synthesized a peptide, corresponding to γ365-383 (designated P3) and tested its ability to inhibit clot retraction. Fig.1A shows that P3 was a strong inhibitor of retraction.
Increasing concentrations of peptide progressively blocked retraction: at 300 µg/ml, the process was inhibited completely, and fibrin clots did not retract after 24 h. The effect of P3 on clot retraction was characterized in detail by using a sensitive assay in which temperature was decreased to 22°C, which retarded the process of retraction and allowed accurate quantification of several kinetic parameters, including the lag-phase, Vmax and the IC 50 (see Experimental
Procedures). Fig 1B shows the rate of clot retraction in the presence of different concentrations of P3. The lag-phase, Vmax and IC 50 values were calculated from the progress curves of retractions ( Table 1 ). The IC 50 value, defined as the concentration of peptide that produced 50% of maximal clot retraction after 2-3 h, was 51 ± 7 µM (Fig. 1C) . The specificity of the To define the active determinants within P3, several overlapping peptides spanning P3 and its flanking regions were synthesized (Table 1) (IC 50 =202 ± 32 µM and 272 ± 12 µM, respectively) compared to 51 ± 7 µM for P3. The activity of γ377-395, which spans the C-terminal part of P3, was low to the point that its kinetic parameters could not be estimated. Based on these results, the majority of P3 activity is likely contained within γ365-377 although the C-terminal part, γ377-383, may contribute to function. (Fig. 3) .
P3 Directly Supports Platelet Adhesion
The capacity of P3 to function as a platelet binding site was verified by using the recombinant γC-domains in which portions of P3 were deleted. The γC-domain without the Cterminal part γ391-411 supported 62 ± 7.3% of the adhesion of nonstimulated platelets compared to that of wild-type γC (Fig. 4) . The sequential truncation of γC resulted in a further decline in the ability of γC(∆377-411) to support platelet adhesion, and γC(∆373-411) and γC(∆370-411) mutants were completely inactive. (∼75%), indicating that α IIb β 3 was primarily responsible for the interaction with P3 (Fig. 6B) .
Adhesion of wild-type CHO cells was partially inhibited by anti-α 5 β 1 mAb (∼55%) and mAb 7E3 was not effective. In parallel experiments, P3 supported strong adhesion of HEK 293 cells which express endogenous α 5 β 1 (not shown).
Integrins α IIb β 3 and α 5 β 1 bind to the P3-bound affinity matrix -To confirm further that P3
interacts with α IIb β 3 and α 5 β 1 , affinity chromatography on a P3-affinity matrix was utilized.
Platelet lysates were applied to P3-agarose and bound material was sequentially eluted with a starting buffer, control peptide H19, 2 mg/ml P3 and 4 M urea. The eluted proteins were analyzed by SDS-PAGE and by Western blotting using mAbs specific for α IIb , β 3 , α 5 and β 1 subunits, and a mAb against Fg. As shown in Fig. 7A , the P3 peptide eluted proteins which migrated as two bands with the molecular weight 120 kDa (α IIb ) 104 kDa (β 3 ). Western blot analyses of the P3-eluted material demonstrated that it contained both α IIb β 3 ( Fig. 7B ) and α 5 β 1 (Fig. 7C ) integrin complexes. A control peptide was not effective, and no Fg was detected in the material eluted with P3 suggesting that the P3 affinity matrix did not retain platelet Fg (Fig. 7A, lane 5) . Additional material, containing both α IIb β 3 and α 5 β 1 , was eluted with 4 M urea. In separate experiments, the lysate of HEK 293 cells, which express endogenous α 5 β 1 , was applied to P3-agarose and eluted material was found to be α 5 β 1 (not shown). Thus, these data confirmed that both integrins α IIb β 3 and α 5 β 1 are capable of binding to P3.
DISCUSSION
In this study, we have identified a sequence in the γC-domain of Fg, γ365-383, which is recognized by platelet integrins α IIb β 3 and α 5 β 1 . P3 synthetic peptide duplicating this sequence, is part of the C-terminal sub-domain and forms an extended loop (Fig. 8) . The N-terminal part of P3, γ365-370, is hidden within the fibrin polymerization cavity and does not appear to be accessible for interaction with receptor whereas the remaining region, γ370-383, is exposed.
The conformation of the C-terminal γ402−411 segment was not determined, and the preceding γ392-402 segment was observed in different conformations (39) . Previous studies have demonstrated that the entire γ392-411 segment is flexible (41-43), and some observations are consistent with the possibility that γ400-411 may fold back such that P3 and AGDV would come in proximity ((44), and our unpublished data). Also, in electron micrographs (3), purified , being 19 residues (∼ 66Å) away from the core of γC. The transformation of Fg to fibrin might change the relationships between γC and its C-terminal part. However, the nature of these alterations is not known and further structural studies will be required to determine the conformation of the C-terminal tail in γC and its relationship with P3.
This study has revealed that integrin α 5 β 1 binds P3 and is involved in platelet adhesion. Previous data have demonstrated that, similar to platelets, recombinant Fg lacking RGD residues supported endothelial cell-mediated clot retraction and adhesion (26, 53) . These data would be consistent with the presence of an additional site on fibrin which is involved in retraction mediated by nucleated cells. Whether P3 binds α 5 β 1 and/or other integrins in these cells during clot retraction and adhesion remains to be determined.
In summary, we have identified the sequence γ370-383, which together with γ Table I Kinetic parameters of clot retraction in the presence of P3 and P3-derived peptides Platelets in isotonic HEPES buffer containing 35 mg/ml BSA, 1 mg/ml glucose, 0.25 mg/ml Fg and 1 mM CaCl 2 were preincubated with different concentrations of peptides for 15 min at 22°C, and then retraction was initiated by adding 1 U/ml thrombin. Clot retraction was monitored and kinetic parameters were determined as described in the "Experimental Procedures" Peptide Sequence IC 50 , µM 
